EA200701166A1 - Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин - Google Patents

Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин

Info

Publication number
EA200701166A1
EA200701166A1 EA200701166A EA200701166A EA200701166A1 EA 200701166 A1 EA200701166 A1 EA 200701166A1 EA 200701166 A EA200701166 A EA 200701166A EA 200701166 A EA200701166 A EA 200701166A EA 200701166 A1 EA200701166 A1 EA 200701166A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alpha
timozyny
antjovants
peptides
cancer vaccines
Prior art date
Application number
EA200701166A
Other languages
English (en)
Other versions
EA015510B1 (ru
Inventor
Густаво Антонио Мовиглия
Алфред Р. Рудолф
Original Assignee
Сциклон Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сциклон Фармасьютикалс, Инк. filed Critical Сциклон Фармасьютикалс, Инк.
Publication of EA200701166A1 publication Critical patent/EA200701166A1/ru
Publication of EA015510B1 publication Critical patent/EA015510B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В заявке описаны фармацевтическая комбинация и способ повышения эффективности противораковой вакцины у субъекта, применение индуцирующей иммунный ответ противораковой вакцины, способной вызывать ответ иммунной системы у субъекта, и количество альфа-тимозинового пептида, повышающего эффективность вакцины, повышающее ответ иммунной системы у субъекта, причем противораковая вакцина и альфа-тимозиновый пептид могут вводиться в организм по отдельности или совместно.
EA200701166A 2004-12-06 2005-12-06 Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация EA015510B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (2)

Publication Number Publication Date
EA200701166A1 true EA200701166A1 (ru) 2008-02-28
EA015510B1 EA015510B1 (ru) 2011-08-30

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701166A EA015510B1 (ru) 2004-12-06 2005-12-06 Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация

Country Status (15)

Country Link
US (1) US20100092499A1 (ru)
EP (1) EP1835931A4 (ru)
JP (1) JP2008523067A (ru)
KR (1) KR20070086663A (ru)
CN (1) CN101072582B (ru)
AU (1) AU2005314271B2 (ru)
BR (1) BRPI0518571A2 (ru)
CA (1) CA2588685A1 (ru)
EA (1) EA015510B1 (ru)
IL (1) IL183264A (ru)
MX (1) MX2007006717A (ru)
NO (1) NO20072705L (ru)
NZ (1) NZ555571A (ru)
UA (1) UA90493C2 (ru)
WO (1) WO2006062917A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079338A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
WO2010129947A2 (en) * 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
CA2826875A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
CN104136040B (zh) * 2012-01-20 2021-05-25 费尔南多·托姆·克罗伊茨 自体癌细胞疫苗
CN104507491A (zh) * 2012-03-08 2015-04-08 赛生制药有限公司 胸腺素α在治疗化脓性鼻窦炎中的应用
TWI749433B (zh) * 2014-10-21 2021-12-11 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
JP2004500029A (ja) * 1999-06-30 2004-01-08 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
MXPA04003864A (es) * 2001-10-26 2004-08-11 Immuno Rx Inc Inmunoterapia para revertir la supresion inmune.
DK1448223T3 (da) * 2001-10-26 2008-02-18 Rhode Island Hospital Thymosin-forögelse af genetisk immunisering
WO2004003174A2 (en) * 2002-06-28 2004-01-08 Sciclone Pharmaceuticals Inc. Method of up-regulating tumor antigen expression using thymalfasin
UA80870C2 (en) * 2003-03-28 2007-11-12 Sciclone Pharmaceuticals Inc Method for treatment or prevention of aspergillus infections with thymosin alpha 1
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
WO2010129947A2 (en) * 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Also Published As

Publication number Publication date
CN101072582A (zh) 2007-11-14
JP2008523067A (ja) 2008-07-03
AU2005314271B2 (en) 2011-06-16
MX2007006717A (es) 2007-08-06
NO20072705L (no) 2007-09-05
CA2588685A1 (en) 2006-06-15
WO2006062917A2 (en) 2006-06-15
US20100092499A1 (en) 2010-04-15
UA90493C2 (ru) 2010-05-11
AU2005314271A1 (en) 2006-06-15
IL183264A0 (en) 2007-09-20
NZ555571A (en) 2009-02-28
CN101072582B (zh) 2012-06-27
EP1835931A2 (en) 2007-09-26
EA015510B1 (ru) 2011-08-30
WO2006062917A3 (en) 2006-11-16
BRPI0518571A2 (pt) 2008-11-25
IL183264A (en) 2010-12-30
KR20070086663A (ko) 2007-08-27
EP1835931A4 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
EA200701166A1 (ru) Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
ES2485316T3 (es) Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
EP2526966A3 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
WO2007103048A3 (en) Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
WO2008054535A3 (en) Novel influenza m2 vaccines
EA200602137A1 (ru) Гидрогелевые препараты интерферона
WO2006115843A3 (en) Nipah virus vaccines
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
MD20100029A (ro) Herpesvirus recombinant al crapului de koi (KHV) sau Cyprinid herpesvirus 3 (CyHV-3) si vaccin pentru prevenirea bolii cauzate de KHV/CyHV-3 la Cyprinus carpio carpio sau Cyprinus carpio koi
CL2009001195A1 (es) Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.
EP4226938A3 (en) Coronavirus vaccine
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
WO2005007673A3 (en) Immunogenic peptides
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
WO2006007555A3 (en) Rotavirus antigens
GB0118532D0 (en) Materials and methods relating to improved vaccination strategies
EA200702079A1 (ru) Вакцина
WO2003093298A3 (en) Immunogenic peptides

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU